Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pierre Fabre Acquires UCB's OTC Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pierre Fabre Acquires UCB’s OTC Business

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pierre Fabre has acquired the OTC business of UCB in France, Benelux, Switzerland and Greece. The acquisition includes certain mature products such as Carbolevure, Revitalose, Balsoclase, Toclase, which represent approximately $23 million in sales. UCB will continue to manufacture and supply some of the transferred products during a transitional period.

The two companies have also have entered into a distribution agreement under which Pierre Fabre will market UCB’s leading anti-histamine, ZyrtecSet, in France.

Pierre-Yves Revol, chief executive officer of Pierre Fabre commented, “The acquisition of UCB’s OTC business in these countries perfectly fits Pierre Fabre’s strategy of developing its healthcare division and enlarge its portfolio with strong brands in France, as well as in countries where the group is already well established. Both Pierre Fabre and UCB product ranges complement each other well and the addition of a new sales team will further increase our OTC presence and strengthen our ties with our pharmacy partners.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters